Cite
HARVARD Citation
Shah, N. et al. (2020). Results from an international phase 2 study of the anti‐CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B‐lineage acute lymphoblastic leukemia. Pediatric blood & cancer. 67 (5), p. n/a. [Online].